{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-047112","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.206260+00:00","generated_at":"2026-05-17T01:36:17.020883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered","bullets":["Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).","Net loss $22.6M (diluted EPS -$0.38) vs loss $5.3M (-$0.09) in Q3 2024.","FY2025 guidance: revenue $210-$230M (prev. $210-$250M); year-end cash $260-$290M (prev. $280-$320M).","Pipeline: Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA Feb 21, 2026; Imsidolimab BLA filing expected Q4 2025.","Cash $293.8M at Sep 30, 2025, down $80.9M from Dec 31, 2024 and $31.8M from Jun 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-047112","json":"https://secwatch.observer/filing/0001628280-25-047112.json","markdown":"https://secwatch.observer/filing/0001628280-25-047112.md","text":"https://secwatch.observer/filing/0001628280-25-047112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/0001628280-25-047112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:36:17.020883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}